Literature DB >> 16224604

Evaluation of the factors interfering with drug treatment compliance among Brazilian patients with schizophrenia.

Moacyr Alexandro Rosa1, Marco Antônio Marcolin, Hélio Elkis.   

Abstract

BACKGROUND: Treatment noncompliance among schizophrenic patients is as high as 50%. In order to rate compliance and assess the most significant differences between compliant and noncompliant patients, a Brazilian population of schizophrenic outpatients was followed for one year.
METHODS: Fifty outpatients were selected. Clinical interview, the Brief Psychiatric Rating Scale--Anchored version (BPRS-A) and an expanded version of the Rating of Medical Influences (ROMI) scale (used to rate patient attitudes toward compliance) were applied at baseline. The BPRS-A was used in the follow-up visits (approximately once a month). Missing two consecutive appointments without explanation or taking less than 75% of the medication (by written family report) was considered noncompliance.
RESULTS: Noncompliance was 48% over one year. Patients in the noncompliant group presented initial worsening of psychotic symptoms (p < 0.05) and had been treated for a shorter length of time (p = 0.007). The ROMI scale showed that "perceived day-to-day benefit" was most strongly correlated with compliance, and feeling "distressed by side effects" was most strongly correlated with noncompliance. DISCUSSION: This study evaluates the frequency of noncompliance and the main reasons for complying in a population of schizophrenic outpatients.
CONCLUSIONS: Severity of psychopathology was found to correlate with noncompliance (although not necessarily as its cause), as well as with duration of treatment. Noncompliance rates are high and must be taken into account in any treatment program.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16224604     DOI: 10.1590/s1516-44462005000300005

Source DB:  PubMed          Journal:  Braz J Psychiatry        ISSN: 1516-4446            Impact factor:   2.697


  11 in total

Review 1.  Medication adherence in schizophrenia.

Authors:  Francisco Javier Acosta; José Luis Hernández; José Pereira; Judit Herrera; Carlos J Rodríguez
Journal:  World J Psychiatry       Date:  2012-10-22

2.  Descriptive analyses of the aripiprazole arm in the risperidone long-acting injectable versus quetiapine relapse prevention trial (ConstaTRE).

Authors:  Rosario de Arce Cordón; Evelin Eding; Joao Marques-Teixeira; Vihra Milanova; Elmars Rancans; Andreas Schreiner
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2011-08-02       Impact factor: 5.270

3.  Quality of life in patients with schizophrenia: the impact of socio-economic factors and adverse effects of atypical antipsychotics drugs.

Authors:  Aurigena Antunes de Araújo; Diego de Araújo Dantas; Gemma Galgani do Nascimento; Susana Barbosa Ribeiro; Katarina Melo Chaves; Vanessa de Lima Silva; Raimundo Fernandes de Araújo; Dyego Leandro Bezerra de Souza; Caroline Addison Carvalho Xavier de Medeiros
Journal:  Psychiatr Q       Date:  2014-09

Review 4.  Defining and assessing adherence to oral antipsychotics: a review of the literature.

Authors:  Dawn I Velligan; Yui-Wing Francis Lam; David C Glahn; Jennifer A Barrett; Natalie J Maples; Larry Ereshefsky; Alexander L Miller
Journal:  Schizophr Bull       Date:  2006-05-17       Impact factor: 9.306

5.  Subjective reasons for adherence to psychotropic medication and associated factors among older adults with schizophrenia.

Authors:  Mamta Sapra; Ipsit V Vahia; Pia N Reyes; Paul Ramirez; Carl I Cohen
Journal:  Schizophr Res       Date:  2008-10-11       Impact factor: 4.939

6.  Long-term remission in schizophrenia and schizoaffective disorder: results from the risperidone long-acting injectable versus quetiapine relapse prevention trial (ConstaTRE).

Authors:  Enrico Smeraldi; Roberto Cavallaro; Vera Folnegović-Šmalc; Leszek Bidzan; Mehmet Emin Ceylan; Andreas Schreiner
Journal:  Ther Adv Psychopharmacol       Date:  2013-08

7.  Clinical outcomes of long-acting injectable risperidone in patients with schizophrenia: six-month follow-up from the Electronic Schizophrenia Treatment Adherence Registry in Latin America.

Authors:  Rogelio Apiquian; Rodrigo Córdoba; Mario Louzã
Journal:  Neuropsychiatr Dis Treat       Date:  2010-12-22       Impact factor: 2.570

8.  Long-acting injectable risperidone in partially adherent and nonadherent patients with schizophrenia.

Authors:  Mário Rodrigues Louzã; Helio Elkis; Sandra Ruschel; Irismar Reis de Oliveira; Rodrigo Affonseca Bressan; Paulo Belmonte-de-Abreu; Hamilton Grabowski; José Carlos Appolinário
Journal:  Neuropsychiatr Dis Treat       Date:  2011-06-23       Impact factor: 2.570

9.  Treatment Discontinuation in Schizophrenia: A Qualitative Exploration from a Rural South Indian Community.

Authors:  K Shanivaram Reddy; Jagadisha Thirthalli; C Naveen Kumar; N Krishna Reddy; Somashekar Bijjal; N R Renuka Devi; Vikram Singh Rawat
Journal:  J Neurosci Rural Pract       Date:  2017 Apr-Jun

10.  Attitudes toward Medication and Reasons for Non-Compliance in Patients with Schizophrenia.

Authors:  Ivatury Sarath Chandra; Kalasapati Lokesh Kumar; Mallepalli Pramod Reddy; Chada Muni Pavan Kumar Reddy
Journal:  Indian J Psychol Med       Date:  2014-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.